4YJS

THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.22 Å
  • R-Value Free: 0.226 
  • R-Value Work: 0.170 
  • R-Value Observed: 0.172 

wwPDB Validation   3D Report Full Report



Literature

Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor.

Liddle, J.Atkinson, F.L.Barker, M.D.Carter, P.S.Curtis, N.R.Davis, R.P.Douault, C.Dickson, M.C.Elwes, D.Garton, N.S.Gray, M.Hayhow, T.G.Hobbs, C.I.Jones, E.Leach, S.Leavens, K.Lewis, H.D.McCleary, S.Neu, M.Patel, V.K.Preston, A.G.Ramirez-Molina, C.Shipley, T.J.Skone, P.A.Smithers, N.Somers, D.O.Walker, A.L.Watson, R.J.Weingarten, G.G.

(2011) Bioorg Med Chem Lett 21: 6188-6194

  • DOI: 10.1016/j.bmcl.2011.07.082
  • Primary Citation of Related Structures:  
    4YJU, 4YJO, 4YJP, 4YJQ, 4YJR, 4YJS, 4YJT, 3SRV

  • PubMed Abstract: 
  • The lead optimisation of the diaminopyrimidine carboxamide series of spleen tyrosine kinase inhibitors is described. The medicinal chemistry strategy was focused on optimising the human whole blood activity whilst achieving a sufficient margin over l ...

    The lead optimisation of the diaminopyrimidine carboxamide series of spleen tyrosine kinase inhibitors is described. The medicinal chemistry strategy was focused on optimising the human whole blood activity whilst achieving a sufficient margin over liability kinases and hERG activity. GSK143 is a potent and highly selective SYK inhibitor showing good efficacy in the rat Arthus model.


    Organizational Affiliation

    GlaxoSmithKline R&D, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, UK. john.2.liddle@gsk.com



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Tyrosine-protein kinase SYKA281Homo sapiensMutation(s): 0 
Gene Names: SYK
EC: 2.7.10.2
Find proteins for P43405 (Homo sapiens)
Explore P43405 
Go to UniProtKB:  P43405
NIH Common Fund Data Resources
PHAROS  P43405
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
4DN
Query on 4DN

Download Ideal Coordinates CCD File 
A
3-[{2-[(1,1-dioxido-2,3-dihydro-1,2-benzothiazol-6-yl)amino]pyrimidin-4-yl}(1H-indazol-4-yl)amino]propan-1-ol
C21 H21 N7 O3 S
XIWBNOAYPAXNEG-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
4DNIC50:  2.2300000190734863   nM  BindingDB
4DNIC50:  0.4099999964237213   nM  BindingDB
4DNIC50:  0.9200000166893005   nM  BindingDB
4DNIC50:  0.75   nM  BindingDB
4DNIC50:  3.440000057220459   nM  BindingDB
4DNIC50:  3.5199999809265137   nM  BindingDB
4DNIC50:  2.2100000381469727   nM  BindingDB
4DNIC50:  3.3499999046325684   nM  BindingDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.22 Å
  • R-Value Free: 0.226 
  • R-Value Work: 0.170 
  • R-Value Observed: 0.172 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 38.407α = 90
b = 84.617β = 100.38
c = 39.756γ = 90
Software Package:
Software NamePurpose
MOSFLMdata reduction
SCALAdata scaling
REFMACrefinement
PDB_EXTRACTdata extraction

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

  • Deposited Date: 2015-03-03 
  • Released Date: 2015-09-30 
  • Deposition Author(s): Somers, D.O.

Revision History 

  • Version 1.0: 2015-09-30
    Type: Initial release